Dexcom

Dexcom is a medical device company that develops continuous glucose monitoring (CGM) systems for people with diabetes. Founded in 1999 and headquartered in San Diego, California, the company received FDA approval for its first CGM in 2006 and has since become one of the two dominant players in the category alongside Abbott's FreeStyle Libre. A Dexcom system uses a small sensor worn on the body that measures glucose levels in interstitial fluid and sends readings to a smartphone or receiver every five minutes, replacing many routine fingerstick tests and alerting users to highs and lows. The current flagship, Dexcom G7, is a compact sensor with a 30-minute warmup that integrates with automated insulin delivery systems from partners such as Tandem Diabetes Care and Insulet's Omnipod, as well as with smartwatches. In 2024 Dexcom launched Stelo, the first glucose biosensor cleared by the FDA for purchase without a prescription in the United States, aimed at adults with type 2 diabetes who do not use insulin and at people focused on metabolic health. Features such as Dexcom Share and Follow let caregivers monitor a user's glucose remotely. Dexcom reports annual revenue around four billion US dollars, employs over 10,000 people, and sells its products in more than 50 countries. The company is publicly traded on Nasdaq and is a component of the S&P 500.